TrialInfection2023
DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
Ildiko Madurka et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
48 papers cite it
this paperpooled ittrialcites it